Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. grew its position in Royalty Pharma plc (NASDAQ:RPRX) by 12.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 36,643 shares of the biopharmaceutical company’s stock after acquiring an additional 4,007 shares during the period. Daiwa Securities Group Inc.’s holdings in Royalty Pharma were worth $1,029,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the company. Allworth Financial LP raised its position in shares of Royalty Pharma by 89.8% in the third quarter. Allworth Financial LP now owns 953 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 451 shares during the period. Toroso Investments LLC raised its position in shares of Royalty Pharma by 0.9% in the third quarter. Toroso Investments LLC now owns 57,102 shares of the biopharmaceutical company’s stock worth $1,550,000 after acquiring an additional 504 shares during the period. EverSource Wealth Advisors LLC raised its position in shares of Royalty Pharma by 112.0% in the third quarter. EverSource Wealth Advisors LLC now owns 1,005 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 531 shares during the period. PNC Financial Services Group Inc. raised its position in shares of Royalty Pharma by 10.8% in the third quarter. PNC Financial Services Group Inc. now owns 5,509 shares of the biopharmaceutical company’s stock worth $150,000 after acquiring an additional 536 shares during the period. Finally, Tokio Marine Asset Management Co. Ltd. raised its position in shares of Royalty Pharma by 8.0% in the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 8,210 shares of the biopharmaceutical company’s stock worth $223,000 after acquiring an additional 607 shares during the period. Institutional investors and hedge funds own 54.35% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on RPRX. JPMorgan Chase & Co. reduced their price target on shares of Royalty Pharma from $45.00 to $42.00 and set an “overweight” rating for the company in a research report on Tuesday, February 20th. StockNews.com upgraded shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Thursday, April 11th. The Goldman Sachs Group reduced their price target on shares of Royalty Pharma from $56.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, February 20th. Finally, Bank of America reduced their price target on shares of Royalty Pharma from $40.00 to $38.00 and set a “buy” rating for the company in a research report on Friday, April 12th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Royalty Pharma presently has a consensus rating of “Buy” and a consensus target price of $46.75.

Royalty Pharma Price Performance

Royalty Pharma stock opened at $27.98 on Thursday. The firm has a market cap of $16.72 billion, a PE ratio of 14.80 and a beta of 0.45. Royalty Pharma plc has a 52-week low of $25.92 and a 52-week high of $35.95. The company has a quick ratio of 7.90, a current ratio of 7.90 and a debt-to-equity ratio of 0.61. The company’s 50 day moving average is $29.69 and its two-hundred day moving average is $28.54.

Royalty Pharma (NASDAQ:RPRX) last released its earnings results on Thursday, February 15th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.03 by $0.12. The company had revenue of $736.00 million for the quarter, compared to analyst estimates of $702.90 million. Royalty Pharma had a net margin of 48.22% and a return on equity of 26.93%. On average, research analysts expect that Royalty Pharma plc will post 3.95 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 17th will be issued a dividend of $0.21 per share. The ex-dividend date is Thursday, May 16th. This represents a $0.84 dividend on an annualized basis and a yield of 3.00%. Royalty Pharma’s dividend payout ratio (DPR) is presently 44.44%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.